Get access

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

Authors

  • M. A. Bookman,

    Corresponding author
    1. Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania and
      Michael A. Bookman, MD, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111 USA. Email: ma_bookman@fccc.edu.
    Search for more papers by this author
  • B. E. Greer,

    1. Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, Washington
    Search for more papers by this author
  • R. F. Ozols

    1. Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania and
    Search for more papers by this author

  • Presented in part as ‘Carboplatin-Paclitaxel vs. Cisplatin-Paclitaxel and Update on GOG0182-ICON5’ 4th International Symposium, Advanced Ovarian Cancer: Optimal Therapy, Update. Valencia, Spain (28 February 03).

Michael A. Bookman, MD, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111 USA. Email: ma_bookman@fccc.edu.

Abstract.

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

Get access to the full text of this article

Ancillary